Xtant Medical (NYSEAMERICAN:XTNT) Announces Earnings Results

Xtant Medical (NYSEAMERICAN:XTNT) announced its quarterly earnings results on Tuesday. The medical device company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02), Zacks reports. The company had revenue of $27.94 million during the quarter. Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. Xtant Medical updated its FY 2024 guidance to EPS.

Xtant Medical Stock Down 4.2 %

XTNT traded down $0.02 during trading on Friday, hitting $0.43. 27,799 shares of the stock were exchanged, compared to its average volume of 101,564. Xtant Medical has a 1 year low of $0.43 and a 1 year high of $1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.01 and a current ratio of 2.12.

Analyst Ratings Changes

Separately, Craig Hallum set a $1.50 price objective on shares of Xtant Medical and gave the company a “buy” rating in a research report on Friday, October 18th.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.